Corporate Banner
Satellite Banner
Genotyping & Gene Expression
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Rosetta Genomics to Receive U.S. Patent for Oncology Therapeutic

Published: Thursday, February 27, 2014
Last Updated: Thursday, February 27, 2014
Bookmark and Share
Company receives a Notice of Allowance from the USPTO for a patent claiming Mp53-negative cancer patients.

The allowed claims for U.S. Patent Application No. 12/528,690 entitled "Composition and Methods for Modulating Cell Proliferation and Cell Death," cover a core element of Rosetta Genomics' microRNA technology in the development of cancer therapeutics associated with non-small cell lung cancer (NSCLC) in p53-negative patients. The allowed patent application is jointly owned with Yeda, the technology transfer company of the Weizmann Institute of Science in Rehovot, Israel.

The p53 protein is a sequence-specific transcription factor that functions as a major tumor suppressor in mammals. Inactivation of the tumor-suppressor function of p53 is one of the most frequent genetic alterations in human cancer, and close to half of all human tumors carry p53 gene mutations within their cells.

The patent discloses the finding that miR-34a, which is a direct transcriptional target of p53, possesses anti-proliferative and pro-apoptotic activities, thereby contributing to the tumor suppressor effects of activated p53. Overexpression of miR-34a exerts anti-proliferative effects and promotes cell death, whereas inactivation of miR-34a attenuates p53-mediated cell death. Thus, miR-34a is a direct transcriptional target of p53, which may mediate some of the biological effects of this tumor suppressor. Perturbation of miR-34a expression may thus contribute to tumorigenesis.

"We continue to fortify our leading intellectual property position in microRNA technology and these newly allowed patent claims expand, strengthen and complement our growing portfolio of over 35 patents worldwide," noted Kenneth A. Berlin, President and Chief Executive Officer of Rosetta Genomics. "This patent is important as it protects key elements of our microRNA technology to develop oncology treatments for NSCLC in p53 negative patients and offers opportunities for monetization. With RNA-based therapeutics, including microRNA-targeting agents, continuing to progress in and towards the clinic, this patent allowance should create opportunities for us to exploit this important new piece of intellectual property. It also supports our broader oncology strategy to develop and commercialize microRNA-based diagnostics, therapeutics and biomarkers that will enhance clinicians' ability to identify and treat cancers."


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Study Shows Potential for microRNAs to Determine Risk of Recurrence in Colorectal Cancer
Rosetta Genomics, Ltd. announced the study has been published in the online edition of the International Journal of Oncology and is expected to appear in the upcoming print edition.
Tuesday, March 20, 2012
Rosetta Genomics Sells Ownership in Rosetta Green
The diagnostics developer announced that it has entered into a Share Transfer Agreement with certain purchasers, pursuant to which it has sold all of the ordinary shares of Rosetta Green Ltd. ("Rosetta Green") it held.
Monday, December 19, 2011
Rosetta Genomics Receives New York State Clinical Laboratory Permit for Its microRNA Diagnostic Tests
Rosetta Genomics, a leading developer and provider of microRNA-based molecular diagnostics, have been issued with a Clinical Laboratory Permit by the New York State Department of Health.
Tuesday, January 04, 2011
Prometheus and Rosetta Genomics Announce License and Collaboration Agreement
MicroRNA-based molecular diagnostics to mark Prometheus' entry into oncology market; Rosetta to receive R&D funding plus future royalties.
Tuesday, April 14, 2009
Rosetta Genomics Reports In-Vivo Efficacy Data for a Systemic MicroRNA Therapeutic for Liver Cancer
Study shows a two-fold decrease in tumor-mass and suppression of the targeted MicroRNA.
Monday, February 16, 2009
Rosetta Genomics Announces Three new Diagnostic Tests to Enter Development
Tests include response prediction to ovarian cancer treatment, predicting gastric cancer recurrence risk, and differentiation of small cell from non-small cell lung cancer.
Friday, June 20, 2008
Henry Ford Hospital and Rosetta Genomics to Develop MicroRNA-based Diagnostics for Brain Cancer
Both parties will conduct a genome-wide molecular analysis of human brain cancer tumors to identify microRNA biomarkers that have diagnostic and prognostic potential.
Tuesday, January 15, 2008
Scientific News
Gene That Lowers Heart Attack Risk Identified
Individuals with a rare twelve-letter deletion from a gene on chromosome 17 have significantly reduced non-HDL cholesterol levels and a 35% lower than average risk of heart disease.
"Sunscreen" Gene May Guard Against Melanoma
USC-led study reveals that melanoma patients with deficient or mutant copies of the gene are less protected from harmful ultraviolet rays.
Myeloid-Derived Suppressor Cells Play Role in Tumor Growth
Researchers at Baylor College of Medicine have reported a new mechanism that helps cancer cells engage myeloid-derived suppressor cells.
Transcription Factor Isoforms Implicated in Colon Diseases
UC Riverside study explains how distribution of two forms of a transcription factor in the colon influence risk of disease.
Roundup Impacts Gene Expression
Study published on the impact of low-dose toxicity of Roundup weed-killer on gene expression profiles.
US-India Collab Finds Molecular Signatures of Severe Malaria
Study may be a significant advancement in understanding the causes of severe malaria.
Big Data Can Save Lives
The sharing of genetic information from millions of cancer patients around the world could be key to revolutionising cancer prevention and care, according to a leading cancer expert from Queen's University Belfast.
Triple-Negative Breast Cancer Target Is Found
Researchers at UC Berkeley discover a target that drives cancer metabolism in triple-negative breast cancer.
Gene Expression Controls Revealed
Researchers have modelled every atom in a key part of the process for switching on genes, revealing a whole new area for potential drug targets.
Using Portable Nanopore DNA Sequencers to Combat Wildlife Crime
University of Leicester researchers aim to develop a test using DNA to identify species at crime scenes in as little as an hour.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!